

TIMOTHY M. KENNEDY
26TH DISTRICT, NEW YORK

WASHINGTON OFFICE
423 CANNON HOB
WASHINGTON, DC 20515
(202) 225-3306

DISTRICT OFFICE
726 EXCHANGE STREET, SUITE 601
BUFFALO, NY 14210
(716) 852-3501

800 MAIN STREET, SUITE 3C
NIAGARA FALLS, 14301
(716) 282-1274



Congress of the United States
House of Representatives
Washington, DC 20515

COMMITTEE ON HOMELAND SECURITY
RANKING MEMBER, SUBCOMMITTEE ON
EMERGENCY MANAGEMENT AND TECHNOLOGY
SUBCOMMITTEE ON TRANSPORTATION AND
MARITIME SECURITY

HOUSE VETERANS' AFFAIRS COMMITTEE
SUBCOMMITTEE ON ECONOMIC OPPORTUNITY
SUBCOMMITTEE ON OVERSIGHT AND
INVESTIGATIONS

REGIONAL WHIP, NEW YORK STATE

CO-CHAIR, NORTHERN BORDER CAUCUS

April 13, 2026

Chairman Tom Cole
2207 Rayburn HOB
Washington, DC 20515

Ranking Member Rosa DeLauro
2413 Rayburn HOB
Washington, DC 20515

Dear Chairman Cole and Ranking Member DeLauro:

I am requesting funding for the Expediting Access to Lifesaving Blood Cancer Treatments project in Fiscal Year 2027. The entity to receive funding for this project is the City of Buffalo, located at 65 Niagara Square, Buffalo, New York 14202. The funding would be used, in partnership with Roswell Park Comprehensive Cancer Center, located at 665 Elm Street, Buffalo, New York 14203, to purchase three next-generation sequencing platforms that will reduce blood cancer testing turnaround times from 5-6 days to under 3 days from clinical order and sample receipt to clinical reporting.

This project is an appropriate use of taxpayer funds because faster sequencing will allow adult and pediatric patients with ALL, AML, MDS, CLL, and lymphoma to begin the right therapy sooner, improving response rates and overall survival outcomes. Roswell Park is a global leader in the development of faster PanHeme assay testing for blood cancers, and this investment will establish one of the fastest blood cancer testing turnaround times in the nation, serving patients across Western New York, Children's Hospital, and partner hospitals throughout the region. Early detection of genetic mutations reduces delays, eliminates unnecessary therapies, and lowers the overall cost of treatment — particularly for high-risk populations, including Hispanic children who are more likely to develop aggressive B-cell ALL.

The project has a federal nexus because the funding provided is for purposes authorized under the Public Health Service Act. I certify that neither I nor my immediate family have any financial interest in this project.

Sincerely,

Timothy M. Kennedy
Member of Congress